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Abstract 
The live plague vaccine strain Y. pestis EV line NIIEG widely used for human and animal immunisation 
proves a high level of specific immunity against both bubonic and pneumonic plague. We constructed an EV NIIEG 
mutant in the acyltransferase gene lpxM that resulted in the production of a less toxic penta-acylated lipid A of 
lipopolysaccharide (LPS) of Y. pestis, tested the synthesis and immunoreactivity of the major known antigens 
involved in virulence and eliciting immunity against plague, and also evaluated the protective properties of the lpxM
derivative.  
The expression of antigens was determined by dot-ELISA, immunoblotting, the indirect hemagglutination 
test, electron microscopy (capsule), and fibrinolytic and plasma-coagulase activities (plasminogen activator Pla). 
Stumulation of TNF-alpha production with different types of LPS was revealed by using the J774 macrophage-like 
cell line. The antibody immune response, followed by immunisation, was estimated by ELISA. Protective efficacy 
was evaluated in mice and guinea pigs by subcutaneous challenge with the wild-type Y. pestis 231.    
In comparison with the parental strain, the lpxM mutant was found to produce a reduced amount of capsular 
antigen F1, multifunctional virulence factor LcrV and murine toxin Ymt as well as had an altered activity of Pla. 
Moreover, this mutant possessed a modified cell surface as jusjed by the immunoreactivity with  monoclonal 
antibodies to different carbohydrate epitopes and by the resistant phenotype to the plague diagnostic bacteriophage 
L-413C. The penta-acylated LPS of Y. pestis revealed a reduced capacity of stimulating TNF-alpha in vitro. 
Immunisation with the lpxM mutant provided an enhanced protection over the original Y. pestis EV NIIEG in both 
mice and guinea pigs. Thus, the pleiotropic effect of the lpxM mutation led to the construction of the live plague 
candidate vaccine strain with improved characteristics toward safety, reactogenicity and protective properties.  
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1. Main text  
     Yersinia pestis, the plague pathogen, is a potential agent for both bioweapons and bioterrorism. Since the end of 
19th century, when the plague bacillus was discovered by Alexander Yersin, a number of vaccines against plague 
have been developed. However, only one of them, a live plague vaccine based on the Y. pestis strain EV76, was 
found to be able to induce a marked level of protection against both bubonic and pneumonic plague. The virulent 
parental strain was initially isolated in 1926 by Girard and Robic from a human case of bubonic plague in 
Madagascar, attenuated by multiple passages in vitro and designated as EV by the initials of the plague patient. The 
Y. pestis strain EV76 is the most frequently used derivative of the EV strain. The strain was transferred to Russia by 
Girard in 1936 from the Pasteur Institute, Tananarive. Since that, its derivative, the Y. pestis EV NIIEG, was used as 
a live plague vaccine in the USSR and has continued to be used in the countries of the Former Soviet Union (FSU) 
and in some former French colonies. From the time of the first human vaccination trials in 1932, different lines or 
subcultures of the EV76 strain including the Y. pestis EV NIIEG, were inoculated into more than 10 million people 
worldwide, having resulted in a considerable decrease of cases of fatal human plague [1-5].  
     The main advantage of the Y. pestis EV NIIEG is its ability to produce a high level of plague immunity in 
vaccinees after a single injection and to provide a relatively prompt (day 7 post-vaccination) and pronounced 
immunity in vaccinees lasting, as documented, for 10–12 months against both bubonic and pneumonic plague. The 
vaccine was found to be effective after administration by different routes, including subcutaneous (s.c.), cutaneous, 
inhalation, and oral applications. The highest level of specific immunity against plague was achieved either by 
scarifying the dermis followed by injection or after vaccination by inhalation [3-5]. 
     The EV NIIEG strain has been reported to be relatively avirulent among the majority of mammalian species, 
including baboons (Papio hamadryas), and showed a relatively low frequency of adverse effects in humans [3]. For 
more than 70 years, there has been no evidence of its reversion to virulence in humans or development of any 
detectable persistence within inoculated individuals [2,3,5]. However, other Y. pestis EV76 derivatives were 
reported to yield severe local and systemic reactions and gross tissue changes in some other species of nonhuman 
primates independent of the route of inoculation [4]. It has been suggested that the majority of the adverse reactions 
are likely to be mediated by the endotoxic activity of the Y. pestis lipopolysaccharide (LPS), due to a capability of 
the plague bacteria to produce a highly toxic hexa-acylated lipid A at ambient temperature, although it was found 
that in vitro at 37oC Y. pestis produced a less toxic tetra-acylated LPS [6-8]. The toxic highly acylated lipid A 
phenotype is provided by the lpxM gene encoding lauroyltransferase. To develop the EV NIIEG derivative with a 
reduced toxicity, a Y. pestis EV NIIEG mutant was constructed by the allelic exchange resulting in deletion of the 
lpxM gene that was demonstrated by PCR using primers flanking the targeted region [8, 9]. The mutant lipid A 
composition was confirmed by structural analysis using high-resolution mass-spectroscopy. As expected, the lpxM-
mutant synthesised at most penta-acylated lipid A which made the strain less toxic for outbred mice than the parent 
one [8]. When the protective activity and residual virulence (innocuity test) of the lpxM mutant and the parental 
vaccine strain were compared, the mutant was found to be completely avirulent and safe in three animal models 
used (outbred mice, guinea pigs, inbred BALB/c mice). In this test, outbred mice were inoculated with 1×105-1×109
CFU of either mutant or EV NIIEG strain, BALB/c mice received 2×102-2.5×104 CFU, and guinea pigs were 
vaccinated with 1×107, 2×109 or 1.5×1010 CFU of either strain. There was no systemic spread or deaths among 
outbred mice and guinea pigs inoculated with the Y. pestis EVǻlpxM mutant. At the same time, among the Balb/c 
mice challenged with the parental Y. pestis EV strain NIIEG, there was at least one vaccine-related death in each of 
the groups given different doses and overall 8 of 28 mice tested died from infection caused by this strain. The Y. 
pestis EV NIIEG bacteria could be found by plating tissue specimens from all dead mice, including those which 
died 20 days post-vaccination. The results obtained with the blood smears confirmed the presence of the Y. pestis 
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EVǻlpxM mutant survived and no tissue specimens positive for Y. pestis were recovered from these animals after 
they were sacrificed at day 21. Moreover, among the guinea pigs vaccinated with the mutant, a two- to threefold 
swelling of the lymph nodes were registered at all immunisation doses given. Notably, less swelling of the lymph 
nodes was found in animals challenged with the Y. pestis EV NIIEG, a characteristic feature of this live vaccine 
strain [9,10].  
     The parent EV NIIEG strain typically provides protection in the range of 50% of mice and guinea pigs against 
200 MLD (2,000 CFU) of a virulent Y. pestis strain [10]. Therefore, to document any potential superiority of the 
lpxM mutant over the current vaccine strain, the challenge dose with virulent Y. pestis was increased by 6-10 fold, 
representing 1,200-2,000 MLD (12,000-20,000 CFU). The animals were immunised by s.c. injection either with the 
mutant or the parental strain, followed by challenge with 12,000-20,000 CFU (1,200-2,000 MLD) of the virulent Y. 
pestis 231 strain (lethal dose50 (LD50) ≤  10 CFU). The efficacy of vaccination was estimated by the number of 
surviving animals. The mutant strain protected both mice and guinea pigs from the high challenge dose of the fully 
virulent Y. pestis strain (85.7% outbred mice against 2,000 MLD, and 42.8% BALB/c mice and 100% guinea pigs 
against 1,200 MLD, respectively) while all animals vaccinated with the parent strain died. These results clearly 
demonstrated a superior efficacy of the ǻlpxM strain in eliciting a protective immunity and demonstrated a 
significant improvement of its immunogenic properties in comparison with the parental Y. pestis EV NIIEG strain. 
     Likely, the decreased adverse effects of the mutant can be directly attributed to the production of a modified less 
toxic LPS. However, it is not apparent why the mutant possessed improved protective properties. One of the 
possible explanations for the increased protective immunity of the lpxM mutant could be an altered expression of 
major immunoreactive antigens that might result in a modification of their presentation to the host immune system. 
Indeed, deleting the lpxM gene in other bacterial pathogens often leads to pleiotropic effects, resulting in membrane 
alterations and attenuation in virulence [11,12]. To test this possibility, the lpxM mutant of the EV NIIEG was 
carefully investigated in respect to the synthesis and immunoreactivity of the known major antigens involved in 
virulence of Y. pestis and development of the immunity against plague. The mutant showed a marked reduction in 
the expression and immunoreactivity as well as changes in the epitope specificity of the major surface proteins, 
which are involved in formation of resistance to phagocytosis, namely the capsule-like envelope antigen “fraction I” 
(F1), Pla protease with versatile virulence-associated functions and V antigen, a multifunctional virulence factor and 
protective antigen of Y. pestis. A marked modification was observed in the biosynthesis or epitope specificity of 
either LPS or galactolipid but not in Enterobacterial Common Antigen (ECA) in the Y. pestis lpxM mutant.  These 
findings were confirmed by analysis of protein profiles using SDS-PAGE. The production of capsular antigen F1, 
Pla protease, V antigen, murine toxin Ymt as well as a few thermoregulated proteins was significantly reduced in the 
mutant in comparison with the parental EV NIIEG strain cultured either at 37oC or at 28oC. These changes were 
accompanied by alterations in the corresponding phenotypic activities. Moreover, the Y. pestis EVǻlpxM bacteria 
had a reduced growth rate and demonstrated an altered resistance to the plague diagnostic bacteriophage L-413C. 
Transmission electron microscopy revealed that a capsule-like substance was produced by the Y. pestis EV NIIEG at 
37oC but not at 28oC, whereas the Y. pestis EVǻlpxM bacteria synthesised little capsule substance at both 
temperatures.  
     Although the production of capsule was reduced in the lpxM mutant, to our surprise, we found that immunisation 
of mice with the mutant strain resulted in better antibody titer to this antigen. Typically, Y. pestis strains produce a 
massive amount of the capsule which may provide an immuno-paralitic effect in high doses, particularly in a guinea 
pig animal model [13]. Therefore, a reduction in the capsule production can be in fact beneficial, perhaps, providing 
a more optimal dose-effect induction of the humoral immune response. 
     Finally, we tested directly a stimulating potency of differently acylated Y. pestis LPS using macrophage-like cell 
line J774. The ability of the hexa-acylated LPS to induce production of TNF-Į was high and similar to that of 
control LPS of E. coli O55:B5. The penta-acylated Y. pestis LPS had a decreased ability to induce the production of 
TNF-Į although it was higher than that of F. tularensis LPS, known for its week endotoxic activity. The tetra-
acylated LPS demonstrated the reduced stimulating activity in comparison with the penta-acylated LPS. 
     In conclusion, we found that: (i) the lpxM mutant of the live plague vaccine strain EV NIIEG displayed improved 
characteristics, such as decreased endotoxic activity and overall reactogenicity, and an enhanced protective 
immunity in comparison with the parental vaccine strain; (ii) the lpxM mutation in Y. pestis caused pleiotropic 
effects resulting in modifications of the biosynthesis and epitope specificity of the major surface proteins and 
carbohydrate antigens accompanied by alterations in the corresponding phenotypic activities; (iii) the Y. pestis 
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more efficient and less toxic live plague vaccines.  
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